Clinical outcomes in men with prostate cancer who selected active surveillance using a clinical cell cycle risk score.
Per Med
; 16(6): 491-499, 2019 11.
Article
en En
| MEDLINE
| ID: mdl-31483217
ABSTRACT
Aim:
To evaluate active surveillance (AS) selection, safety and durability among men with low-risk prostate cancer assessed using the clinical cell cycle risk (CCR) score, a combined clinical and molecular score. Patients &methods:
Initial treatment selection (AS vs treatment) and duration of AS were evaluated for men with low-risk prostate cancer according to the CCR score and National Comprehensive Cancer Network guidelines. Adverse events included biochemical recurrence and metastasis.Results:
82.4% (547/664) of men initially selected AS (median follow-up 2.2 years), 0.4% (2/547) of whom experienced an adverse event. Two-thirds of patients remained on AS for more than 3 years; patient choice was the most common reason for leaving AS.Conclusion:
The CCR score may aid in the identification of men who can safely defer prostate cancer treatment.Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Neoplasias de la Próstata
/
Medición de Riesgo
/
Espera Vigilante
Tipo de estudio:
Etiology_studies
/
Guideline
/
Prognostic_studies
/
Risk_factors_studies
/
Screening_studies
Límite:
Humans
/
Male
Idioma:
En
Año:
2019
Tipo del documento:
Article